Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP05077584A	2011-03-15	APOTEX INC.	Revoked
EP04755691A	2008-06-11	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7326708	June, 2020	Final Written Decision	Merck Sharp & Dohme Corp. et al.	Sun Pharmaceutical Industries Ltd. et al.
US7326708	June, 2020	Final Written Decision	Merck Sharp & Dohme Corp. et al.	Dr. Reddy's Laboratories, Inc. et al.
US7326708	June, 2020	Terminated-Settled	Merck Sharp & Dohme Corp.	Teva Pharmaceuticals USA, Inc.
US7326708	October, 2019	Final Written Decision	Merck Sharp & Dohme Corp. et al.	Mylan Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (1 year, 2 months ago)
US7326708	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	Nov, 2026 (3 years from now)
US8080580	MERCK SHARP DOHME	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	Jul, 2030 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871 (Pediatric)	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan, 2023 (8 months ago)
US7326708 (Pediatric)	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May, 2027 (3 years from now)
US9439901	MERCK SHARP DOHME	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	Oct, 2030 (7 years from now)
US9308204	MERCK SHARP DOHME	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	Oct, 2030 (7 years from now)

Steglujan is owned by Merck Sharp Dohme.

Steglujan contains Ertugliflozin; Sitagliptin Phosphate.

Steglujan has a total of 7 drug patents out of which 2 drug patents have expired.

Expired drug patents of Steglujan are:

Steglujan was authorised for market use on 19 December, 2017.

Steglujan is available in tablet;oral dosage forms.

Steglujan can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The generics of Steglujan are possible to be released after 21 October, 2030.

Drug Exclusivity	Drug Exclusivity Expiration
M (M)	Sep 17, 2024

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG;EQ 100MG BASE	TABLET;ORAL	Prescription
15MG;EQ 100MG BASE	TABLET;ORAL	Prescription

STEGLUJAN family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic